CompletedNCT01347944

MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry

Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Celgene
Principal Investigator
Sante Cundari, PhD, MSc
Celgene s.r.l.
Intervention
lenalidomide(drug)
Enrollment
149 enrolled
Eligibility
18 years · All sexes
Timeline
20112013

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01347944 on ClinicalTrials.gov

Other trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Additional recruiting or active studies for the same condition.

See all trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

← Back to all trials